Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · HexarelinWeak / none
Hexarelin promotes the survival of retinal ganglion cells after optic nerve transection.
Here hexarelin is the actual intervention, administered to golden hamsters after optic-nerve transection to test whether it protects retinal ganglion cells. Researchers reported dose-dependent increases in cell survival: single daily doses of 25, 50 and 100 µg/kg raised survival from about 51% (saline) to 62%, 69% and 75% respectively over 7 days, and twice-daily dosing (100 and 150 µg/kg) raised it further, to roughly 91% and 109% of the saline reference. This is a genuine hexarelin signal in a neuroprotection model, consistent with the peptide's described anti-apoptotic activity. Caveats: a single-species rodent model, a narrow survival endpoint, and no functional-vision measures. These are preclinical findings; human data would be needed before any clinical conclusion.
Indian journal of pharmacologyn=—AnimalMar 1, 2026 - Study · AOD-9604Weak / none
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
This narrative review is directly on-topic for several tracked peptides. It maps the performance-enhancing GH-IGF-1 axis compounds sold as research chemicals, including the GHRH analogues sermorelin, tesamorelin, and CJC-1295 (with and without DAC), and the growth-hormone secretagogues GHRP-6, hexarelin, and ipamorelin. Its central contribution is an evidence-tiering: the authors contrast peer-reviewed pharmacology and clinical data against the online self-administration protocols people actually use, stratifying agents from regulatory-grade trial evidence down to a complete absence of human studies, and they are explicit that performance and body-recomposition benefits remain unproven. They also catalogue reported adverse effects, including prolactin and cortisol elevations, fluid retention, joint and muscle symptoms, and injection-site reactions. As a review it introduces no new data, but for readers weighing these secretagogues it is a sober, caveat-forward map of how thin the human evidence is and what risks have been reported.
Frontiers in endocrinologyn=——Jan 1, 2026